Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Determinants of response and resistance to T-cell engaging therapies in multiple myeloma

Shonali Midha, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a study which evaluated determinants of response and resistance to BCMA-directed bispecific antibodies in patients with multiple myeloma, highlighting the impact of CD4 and CD8 T-cell populations prior to treatment. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Pfizer, AbbVie